Semaglutide is not approved for use during pregnancy, and manufacturers recommend stopping it at least two months before attempting to conceive. However, the weight loss semaglutide provides may actually improve fertility outcomes for patients with obesity-related reproductive challenges. The relationship between semaglutide and fertility is nuanced and depends on your individual situation.

As GLP-1 medications become more widely prescribed for weight management, questions about their impact on reproductive health have increased significantly. This is especially relevant for women of childbearing age, who represent a large portion of patients seeking weight loss treatment.

Why Semaglutide Should Be Stopped Before Pregnancy

Semaglutide has a long half-life of approximately seven days, meaning it stays active in the body well after the last injection. The prescribing information for both Ozempic and Wegovy recommends discontinuing semaglutide at least two months before a planned pregnancy.

Animal studies showed some evidence of embryo-fetal toxicity at high doses, including early pregnancy loss and developmental abnormalities. While these findings occurred at doses much higher than those used in humans, the precautionary recommendation stands because adequate human pregnancy data is limited.

How Weight Loss From Semaglutide May Improve Fertility

Obesity is one of the most common modifiable risk factors for infertility in both men and women. Excess body weight can disrupt hormonal balance, ovulation regularity, sperm quality, and the success rates of assisted reproduction.

For women, losing even 5% to 10% of body weight can:

• Restore regular ovulation in patients with polycystic ovary syndrome (PCOS)
• Improve hormonal profiles including estrogen, progesterone, and luteinizing hormone
• Increase success rates of IVF and other fertility treatments
• Reduce the risk of pregnancy complications like gestational diabetes and preeclampsia

For men, weight loss can improve testosterone levels, sperm count, and sperm motility. Some reproductive endocrinologists now recommend a period of weight loss with GLP-1 medication before fertility treatment, followed by an appropriate washout period.

Semaglutide and PCOS

Polycystic ovary syndrome affects an estimated 8% to 13% of women of reproductive age, and many of those affected also have insulin resistance and difficulty managing weight. Semaglutide's dual action on weight and blood sugar regulation may benefit women with PCOS by improving insulin sensitivity and promoting weight loss, both of which can help restore ovulatory cycles.

Some early research and clinical observations suggest that women on GLP-1 medications may experience a return of ovulation they did not expect, sometimes referred to informally as "Ozempic babies." This underscores the importance of using reliable contraception while on semaglutide if pregnancy is not desired. semaglutide and PCOS

Contraception Considerations

Because GLP-1 medications slow gastric emptying, there is a theoretical concern that oral contraceptive absorption could be affected. The FDA has noted this possibility and some providers recommend using a non-oral backup method of contraception (such as an IUD, implant, or condoms) while taking semaglutide. Discuss your contraceptive method with your provider when starting semaglutide.

Male Fertility and Semaglutide

Research on semaglutide's direct effects on male fertility is limited. Animal studies have not shown significant negative effects on male reproductive function at standard doses. The indirect benefit of weight loss improving testosterone and sperm quality may outweigh theoretical risks for many men. However, men planning to conceive should also discuss the timeline with their provider.

Frequently Asked Questions